The FDA’s next five-year Prescription Drug User Fee Act (PDUFA VIII) reauthorization includes “America First” provisions alongside faster reviews for some application types and updated ways for industry to communicate during review. The package is aimed at tightening timelines while aligning incentives for domestic drug development and manufacturing. For biotech and pharma sponsors, the program details may influence development budgeting and launch planning by changing review dynamics and the expected schedule for certain submissions. Even when clinical outcomes drive approvals, user-fee frameworks can materially affect time-to-decision and operational planning.